Fasano, S;
Alves, SC;
Isenberg, DA;
(2016)
Current pharmacological treatment of idiopathic inflammatory myopathies.
Expert Review of Clinical Pharmacology
, 9
(4)
pp. 547-558.
10.1586/17512433.2016.1136561.
Preview |
Text
Fasano_Current pharmacological treatment of idiopathic inflammatory myopathies.pdf - Accepted Version Download (253kB) | Preview |
Abstract
The idiopathic inflammatory myopathies are uncommon and heterogeneous disorders. Their classification is based on distinct clinicopathologic features. Although idiopathic inflammatory myopathies share some similarities, different subtypes may have variable responses to therapy, so it is very important to distinguish the correct subtype. There are few randomised, double blind placebo controlled studies to support the current treatment. High dose corticosteroids continue to be the first-line therapy and other immunosupressive drugs are used in refractory cases, as well as steroid-sparing agents. Some novel therapeutic approaches have emerged as potential treatment including tacrolimus, intravenous immunoglobulin and rituximab, following good outcomes reported in case studies. However, more randomised controlled trials are needed. This review considers the current and the potential future therapies for inflammatory myopathies.
| Type: | Article |
|---|---|
| Title: | Current pharmacological treatment of idiopathic inflammatory myopathies |
| Open access status: | An open access version is available from UCL Discovery |
| DOI: | 10.1586/17512433.2016.1136561 |
| Publisher version: | http://dx.doi.org/10.1586/17512433.2016.1136561 |
| Language: | English |
| Additional information: | Copyright © 2016 Taylor & Francis. This is an Accepted Manuscript of an article published by Taylor & Francis in Expert Review of Clinical Pharmacology, on 6 February 2016, available online: http://dx.doi.org/10.1586/17512433.2016.1136561 |
| Keywords: | Science & Technology, Life Sciences & Biomedicine, Pharmacology & Pharmacy, Idiopathic inflammatory myopathy, inclusion body myositis, treatment, dermatomyositis, polymyositis, Inclusion-body Myositis, Stem-cell Transplantation, Interstitial Lung-disease, Alpha Monoclonal-antibody, Necrosis-factor-alpha, Of-the-literature, Juvenile Dermatomyositis, Intravenous Immunoglobulin, Refractory Polymyositis, Double-blind |
| UCL classification: | UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Div of Medicine UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Div of Medicine > Inflammation |
| URI: | https://discovery-pp.ucl.ac.uk/id/eprint/1536416 |
Archive Staff Only
 |
View Item |
